<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736096</url>
  </required_header>
  <id_info>
    <org_study_id>MUCOVIR (2017-A02380-53)</org_study_id>
    <nct_id>NCT03736096</nct_id>
  </id_info>
  <brief_title>Molecular Diagnosis of Respiratory Viral Infections on Sputum From Cystic Fibrosis Patients</brief_title>
  <acronym>MUCOVIR</acronym>
  <official_title>Validation du Diagnostic moléculaire Des Infections Virales Respiratoires Sur Les Expectorations Des Patients Atteints de Mucoviscidose Validation of the Molecular Diagnosis of Respiratory Viral Infections on the Sputum of Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this project is to evaluate the agreement between nasopharyngeal and
      sputum specimens in terms of detection of viral infection in Cystic Fibrosis (CF)
      participants.This is a 12-month national, multicenter prospective study (7 centers).
      Inclusions concern CF participants (children or adults) with signs of acute respiratory
      infection seen in consultation or hospitalized in their CF Research Center. A molecular viral
      multiplex search is performed on both nasopharyngeal and expectoration collected samples for
      each included participant. Determination of viral detection agreement between the two CF
      respiratory samples is then performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Viral respiratory infections in cystic fibrosis (CF) have a significant impact on the
      progression of the disease. It is therefore essential to look for these viruses. No
      recommendations are made for the virological follow-up of CF patients and no optimal strategy
      for the type of sampling required. In non-CF patients, the search for a viral infection is
      performed by nasopharyngeal sampling. This method of sampling is invasive and uncomfortable
      for the patient. In CF patients, sputum, non-invasive sampling, is routinely used for
      bacterial research and may be used for viral infections to avoid invasive nasopharyngeal
      sampling in patients whose management is heavy.

      After giving consent, both sputum and nasopharyngeal swab are collected for each participant.
      A record of clinical and biological data is also made at inclusion. A molecular viral search
      is performed on both samples by a multiplex technique detecting a broad spectrum of
      respiratory viruses. A bacteriological analysis is carried out on sputum. The molecular
      results will be interpreted blindly according to the main criterion of evaluation, presence
      or absence of viral infection.

      Comparison of expectoration to nasopharyngeal sampling of CF patients for respiratory
      virological diagnosis should analyse agreement of the molecular viral detection and position
      CF sputum as an optimal assay for respiratory viruses with the advantage of not being
      invasive and in all cases routinely taken for the control and bacterial follow-up.

      The promotion of sputum as an ad hoc sampling for viral research and epidemiology would
      facilitate the establishment of surveillance for viral infections in cystic fibrosis and
      thereby contribute to the CF register data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2018</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance of viral type detected in both samples for each participant: sputum and nasopharyngeal swab</measure>
    <time_frame>Day 1</time_frame>
    <description>Comparison of per participant results of viral molecular detection in both sputum and nasapharyngeal samples: 18 different types of respiratory viruses may be qualitatively detected by Molecular analyses (multiplex PCR) the Outcome Measure results will be reported as number of participants with same virus type in both sample - number participant with different virus detected in the two samples - number of participants with no virus detected in both samples - number of participants with one virus detected in nasapharyngeal and no virus in sputum - number of participant with no virus detected in nasopharyngeal and one virus detected in sputum - and so on for every possible combinations</description>
  </primary_outcome>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Acute Respiratory Infection</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      sputum and nasopharyngeal swab from expectorant CF participants retained at -80°C
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        participant living with Cystic Fibrosis disease presenting an acute respiratory infection
        cared in french pediatric or adult Center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  participant with Cystic Fibrosis

          -  participant with sign of acute respiratory infection

          -  participant able to expectorate

        Exclusion Criteria:

          -  participant not able to expectorate

          -  participant refusing to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sophie VALLET</last_name>
    <phone>02 98 14 51 01</phone>
    <email>sophie.vallet@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'ANGERS</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise Troussier, Pr</last_name>
      <email>FrTroussier@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry URBAN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muriel LAURANS</last_name>
      <email>laurans-m@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de NANTES</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Melon</last_name>
      <email>vvdavid@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle DANNER-BOUCHER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital TROUSSEAU</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hariet CORVOL</last_name>
      <email>harriet.corvol@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de PERHARIDY</name>
      <address>
        <city>Roscoff</city>
        <zip>29684</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie RAMEL</last_name>
      <email>sophie.ramel@ildys.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital FOCH</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique GRENET</last_name>
      <email>d.grenet@hopital-foch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Julie MANKIKIAN</last_name>
      <email>JMANKIKIAN@chu-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>November 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>November 7, 2018</last_update_submitted>
  <last_update_submitted_qc>November 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>sputum</keyword>
  <keyword>nasopharyngeal swab</keyword>
  <keyword>viral molecular diagnosis</keyword>
  <keyword>respiratory infection</keyword>
  <keyword>expectoration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

